About Non-small Cell Lung Cancer
Non-small cell lung cancer occurs when normal cells grow and multiply without control after undergoing a cell transformation. Lung cancer is the leading cause of cancer deaths worldwide, and the incidence of lung cancer is increasing significantly. Lung cancer is the common cause of mortality and morbidity not only in developed countries but also in developing countries. One of the most common types of lung cancer is non-small cell lung cancer. It grows and spreads quite slowly. Smoking is considered as a major cause of lung cancer, although lung cancer also occurs in non-smokers. There are three main types of non-small cell lung cancer: squamous cell (epidermoid) carcinoma, adenocarcinoma, and large cell (undifferentiated) carcinoma. Some of the common symptoms associated with non-small cell lung cancer are chest pain, a cough that does not go away, coughing up blood, fatigue, loss of appetite, losing weight without trying, shortness of breath, and wheezing.
TechNavio's analysts forecast the Global Non-small Cell Lung Cancer market to grow at a CAGR of 3.62 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Non-small Cell Lung Cancer market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through various therapies adopted for the treatment of non-small cell lung cancer, including
• Biologics
• Small Molecules
TechNavio's report, the Global Non-small Cell Lung Cancer Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Non-small Cell Lung Cancer market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• AstraZeneca
• Celgene
• Eli Lilly
• F. Hoffmann-La Roche
• Pfizer
Other Prominent Vendors
• Aetna
• Boehringer Ingelheim
• Celldex
• Eisai
• GlaxoSmithKline
• IMClone
• Merck Serono
• Novartis
• Qiagen
• OncoGenex
• OSI Pharmaceuticals
• Pierre Fabre
• Sanofi
• Synta
Market Driver
• High Unmet Needs
• For a full, detailed list, view our report
Market Challenge
• High Cost of Therapy
• For a full, detailed list, view our report
Market Trend
• Availability of Personalized Medicine
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Iressa
04.1.2 Abraxane
04.1.3 Alimta
04.1.4 Gemzar
04.1.5 Xalkori
04.1.6 Avastin
04.1.7 Tarceva
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Molecule Type
08.1 Biologics
08.2 Small Molecules
09. Market Segmentation by Route of Administration
09.1 Oral
09.2 Parenteral
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.3 AstraZeneca
18.3.1 Iressa
18.4 Celgene
18.4.1 Abraxane
18.5 Eli Lilly
18.5.1 Alimta
18.5.2 Gemzar
18.6 Pfizer
18.6.1 Xalkori
18.7 Roche
18.7.1 Avastin
18.7.2 Tarceva
18.8 Other Prominent Vendors
19. Pipeline Portfolio
20. Key Vendor Analysis
20.1 AstraZeneca plc
20.1.1 Key Facts
20.1.2 Business Description
20.1.3 Business Segmentation
20.1.4 Business Strategy
20.1.5 Revenue by Business Segmentation
20.1.6 Revenue Comparison 2011-2013
20.1.7 Sales Revenue by Geographical Segmentation
20.1.8 Key Developments
20.1.9 SWOT Analysis
20.2 Celgene
20.2.1 Key Facts
20.2.2 Business Description
20.2.3 Business Strategy
20.2.4 Business Segmentation by Revenue 2011-2013
20.2.5 Sales by Geography
20.2.6 Key Developments
20.2.7 SWOT Analysis
20.3 Eli Lilly
20.3.1 Key Facts
20.3.2 Business Overview
20.3.3 Business Segmentation by Revenue 2013
20.3.4 Business Segmentation by Revenue 2012 and 2013
20.3.5 Sales by Geography
20.3.6 Business Strategy
20.3.7 Key Developments
20.3.8 SWOT Analysis
20.4 Pfizer
20.4.1 Key Facts
20.4.2 Business Description
20.4.3 Business Segmentation
20.4.4 Revenue by Business Segmentation
20.4.5 Revenue Comparison 2012 and 2013
20.4.6 Sales by Geography
20.4.7 Business Strategy
20.4.8 Key Developments
20.4.9 SWOT Analysis
20.5 Roche
20.5.1 Key Facts
20.5.2 Business Overview
20.5.3 Business Segmentation by Revenue 2013
20.5.4 Business Segmentation by Revenue 2012 and 2013
20.5.5 Geographical Segmentation by Revenue 2013
20.5.6 Business Strategy
20.5.7 Recent Developments
20.5.8 SWOT Analysis
21. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Non-Small-Cell Lung Cancer Market 2013-2018 (US$ billion)
Exhibit 3: Global Non-Small-Cell Lung Cancer Market Segmentation by Molecule Type
Exhibit 4: Global Non-Small-Cell Lung Cancer Market Segmentation by Molecule Type 2013
Exhibit 5: Global Non-Small-Cell Lung Cancer Market Segmentation by Route of Administration
Exhibit 6: Global Non-Small-Cell Lung Cancer Market Segmentation by Route of Administration 2013
Exhibit 7: Global Non-Small-Cell Lung Cancer Market by Geographical Segmentation 2013
Exhibit 8: Global Non-Small-Cell Lung Cancer Market Share Analysis 2013
Exhibit 9: Sales Comparison of Major Drugs 2010-2013 (US$ million)
Exhibit 10: AstraZeneca's Iressa Sales Comparison 2006-2013 (US$ million)
Exhibit 11: Iressa Sales Comparison in Western Europe 2009-2013 (US$ million)
Exhibit 12: Iressa Sales Comparison in the Established ROW 2009-2013 (US$ million)
Exhibit 13: Iressa Sales Comparison in the Emerging Markets 2009-2013 (US$ million)
Exhibit 14: Region-wise Total Sales Comparison of Iressa 2009-2011 (US$ million)
Exhibit 15: Sales Comparison of Abraxane 2009-2013 (in US$ million)
Exhibit 16: Sales Comparison of Alimta 2003-2011 in the US (US$ million)
Exhibit 17: Sales Comparison of Alimta 2003-2011 Outside the US (US$ million)
Exhibit 18: Total Sales Comparison of Alimta 2003-2011 (US$ million)
Exhibit 19: Region-wise Total Sales Comparison of Alimta 2003-2011 (US$ million)
Exhibit 20: Sales Comparison of Gemzar in the US 2003-2011 (US$ million)
Exhibit 21: Sales Comparison of Gemzar Outside the US 2003-2011 (US$ million)
Exhibit 22: Worldwide Total Sales Comparison of Gemzar 2003-2011 (US$ million)
Exhibit 23: Region-wise Total Sales Comparison of Gemzar 2003-2011 (US$ million)
Exhibit 24: Sales Forecast of Xalkori 2013-2018 (US$ million)
Exhibit 25: Sales Comparison of Avastin and Tarceva 2005-2013 (in US$ million)
Exhibit 26: Sales Comparison of Avastin 2005-2013 (US$ million)
Exhibit 27: Sales Comparison of Tarceva 2005-2013 (US$ million)
Exhibit 28: Late Stage Pipeline Molecules for Non-Small-Cell-Lung Cancer
Exhibit 29: AstraZeneca plc: Business Segmentation
Exhibit 30: AstraZeneca plc: Revenue by Business Segmentation2013
Exhibit 31: AstraZeneca plc: Revenue by Business Segmentation 2011-2013 (US$ billion)
Exhibit 32: AstraZeneca plc: Sales Revenue by Geographical Segmentation 2013
Exhibit 33: Celgene Corp.: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 34: Celgene Corp.: Sales by Geography 2013
Exhibit 35: Eli Lilly and Co.: Business Segmentation by Revenue 2013
Exhibit 36: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 37: Eli Lilly and Co.: Sales by Geography 2013
Exhibit 38: Pfizer Inc.: Business Segmentation
Exhibit 39: Pfizer Inc.: Revenue by Business Segmentation 2013
Exhibit 40: Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
Exhibit 41: Pfizer Inc.: Revenue by Geography 2013
Exhibit 42: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 43: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 44: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Pharmaceuticals Division)
Exhibit 45: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Diagnostics Division)
